Ionis Forges $30M Ex-US Rare Disease Pact with Recordati, Accelerating Global ASO Reach

June 28, 2026

Fierce Biotech USA

Overview

Ionis Pharmaceuticals has secured a $30 million upfront payment from Recordati, granting the Italian firm exclusive ex-US development and commercialization rights for specific rare disease therapies. This strategic partnership accelerates Ionis’s global expansion of its rare disease pipeline and enhances access to innovative antisense oligonucleotide (ASO) treatments for a broader international patient population.

In Depth

Background

Rare diseases, by their very nature, affect a small number of patients globally, presenting unique challenges for drug development that demand substantial investment and specialized expertise. However, therapies targeting these conditions often receive ‘orphan drug’ designation, providing incentives such as market exclusivity periods to help pharmaceutical companies recoup significant research and development costs. Ionis Pharmaceuticals stands as a pioneer in antisense oligonucleotide (ASO) technology, developing drugs that address the root causes of many genetic rare diseases by precisely targeting gene expression. Partnering with established international firms like Recordati, an Italian pharmaceutical company specializing in rare diseases and specialty pharmaceuticals, offers a strategic pathway for R&D-focused biotech companies like Ionis to secure funding and navigate the complexities of global commercialization efficiently. ASO technology has, in recent years, delivered significant breakthroughs in the treatment landscape for numerous previously untreatable rare conditions.

Key Findings

Ionis Pharmaceuticals has granted Recordati exclusive development and commercialization rights for specific rare disease therapies outside the United States, securing an immediate $30 million upfront payment. This collaboration represents a critical strategic step for Ionis to accelerate the global deployment of its rare disease pipeline and deliver groundbreaking treatments to a wider patient population. While specific names or mechanisms of action for the drugs included in this agreement were not detailed in the report, Ionis’s robust portfolio encompasses ASO therapies for multiple rare conditions, including hereditary angioedema, familial amyloid polyneuropathy, and spinal muscular atrophy. Recordati’s established expertise in rare diseases and specialty medical fields positions it strongly to maximize the success of Ionis’s innovative drugs across Europe and other ex-U.S. markets.

Significance & Outlook

The $30 million upfront payment significantly bolsters Ionis’s financial position, providing capital for reinvestment into its promising pipeline of other ASO candidates and further advancing its proprietary technology platform. For Recordati, this partnership expands its rare disease portfolio with cutting-edge therapies, thereby strengthening its market presence in key therapeutic areas. This collaboration promises to substantially improve patient access to much-needed treatments in regions with high unmet medical needs for rare diseases. Future attention will focus on the progression of clinical development for the targeted therapies and the execution of Recordati’s commercialization strategy in these vital international markets, ultimately benefiting rare disease patients worldwide.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.